{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-011132","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.487841+00:00","generated_at":"2026-06-25T23:31:11.865113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Puma Biotechnology Q1 net loss $3.4M, product revenue down 11% to $40.7M","bullets":["GAAP net loss of $3.4M ($0.08 per share) vs net income of $16.5M ($0.41) in Q1 2021.","Total revenue $45.7M vs $98.2M; product revenue $40.7M (down 11% YoY); royalty revenue $5.0M.","Non-GAAP adjusted net loss $0.3M ($0.01 per share) vs adjusted net income $22.4M ($0.56) a year ago.","Cash and marketable securities $73.9M at March 31, 2022, down from $82.1M at Dec 31, 2021.","Upcoming milestones for neratinib trials: SUMMIT Phase II data in HER2-mutated breast cancer and biliary tract cancer H1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-011132","json":"https://secwatch.observer/filing/0001437749-22-011132.json","markdown":"https://secwatch.observer/filing/0001437749-22-011132.md","text":"https://secwatch.observer/filing/0001437749-22-011132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922011132/0001437749-22-011132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922011132/pbyi20220504_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:31:11.865113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}